Arcede Pharma, Iconovo and Lund University has received just over SEK 2 million from Swelife for the development of the inhaled treatment RCD405 for COPD and severe asthma. The grant will be used to develop an inhalation product for use in clinical studies and continue to study the candidate's dual mechanism of action.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.098 SEK | -2.00% |
|
+3.38% | +7.69% |
2023 | Arcede Pharma Announces CEO Changes | CI |
2023 | Arcede Pharma and Iconovo AB Takes the Next Step in the Development of a New Treatment for COPD | CI |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
9.1 SEK | -4.81% | -8.08% | 14.47M | ||
0.098 SEK | -2.00% | +3.38% | 55.85K | ||
- Stock Market
- Equities
- ARCEDE Stock
- News Arcede Pharma AB
- Arcede Pharma and Iconovo Receive Funding from Swelife